Korro Bio (KRRO) Receivables (2024 - 2025)
Korro Bio's (KRRO) quarterly Receivables came in at $969000.0 in Q4 2025, down 42.87% on a YoY basis from $1.7 million in Q4 2024, and up 18.17% quarter-over-quarter from $820000.0 in Q3 2025.
Powered by 
Analysis
Korro Bio (KRRO) Receivables (2024 - 2025) Analysis & Trends
Korro Bio (KRRO) has reported Receivables for 2 consecutive years, with $969000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Receivables fell 42.87% year-over-year to $969000.0; the trailing twelve-month figure through Dec 2025 stood at $969000.0 (down 42.87% YoY), and the FY2025 full-year result was $1.0 million, down 41.18% from the prior year.
- Receivables grew to $969000.0 in Q4 2025 per KRRO's latest filing, from $820000.0 in the prior quarter.
- Across five years, Receivables topped out at $10.0 million in Q3 2024 and bottomed at $820000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Korro Bio | 231.15 Mn | 116.12 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 969,000.00 |
| Sep 30, 2025 | 820,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 10.00 Mn |